Mild compositions for preventive anti-aging of sensitive skin, their preparation methods and applications

By combining ectoine, bakuchiol liposomes, and ceramide liposomes, we have addressed the multidimensional anti-aging issues of sensitive skin, achieving a synergistic effect of blocking aging signals, activating collagen regeneration, and rebuilding the skin barrier under low irritation.

CN123101418APending Publication Date: 2026-11-17SHANGHAI MCGILL DAILY NECESSITIES CO LTD
View PDF 2 Cites 0 Cited by

Patent Information

Application Number
CN202611401588.0
Authority / Receiving Office
CN · China
Patent Type
Applications(China)
Current Assignee / Owner
Filing Date
2026-09-10
Publication Date
2026-11-17

AI Technical Summary

Technical Problem

Existing technologies struggle to achieve multi-dimensional anti-aging effects on sensitive skin without compromising skin tolerance, especially in simultaneously blocking aging signals, activating collagen regeneration, and rebuilding the skin barrier function.

Method used

By employing a combination of ectoine, psoralen liposomes, and ceramide liposomes, and through a differentiated delivery strategy, ectoine exists in a free form, while psoralen and ceramide are encapsulated in liposomes, achieving a synergistic effect of upstream blockade, midstream anti-aging, and downstream barrier reconstruction.

Benefits of technology

With low irritation, it achieves preventative anti-aging for sensitive skin, blocks aging signals, activates collagen regeneration and rebuilds the skin barrier, providing comprehensive anti-aging protection.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN123101418A_ABST
    Figure CN123101418A_ABST
Patent Text Reader

Abstract

This invention relates to the field of cosmetic technology, disclosing a mild composition for preventative anti-aging of sensitive skin, its preparation method, and its application. The composition comprises ectoine, bakuchiol liposome suspension, and ceramide liposome suspension, in a mass ratio of (0.01~4):(0.01~6):(0.01~7). Based on the vicious cycle of "fragile barrier - accumulated inflammation - accelerated aging" in sensitive skin, this invention constructs a triple synergistic framework of upstream preventative blocking, midstream proactive anti-aging, and downstream barrier structural reconstruction. Ectoine blocks the transformation of stimulus signals into inflammatory aging at the source; bakuchiol liposomes inhibit inflammation and promote collagen synthesis; and ceramide liposomes rebuild the stratum corneum barrier. Bakuchiol and ceramide are encapsulated in liposomes, while ectoine exists in a free form, with complementary release sequences. This invention overcomes the limitations of the staged strategy of "repair first, then anti-aging" and is suitable for long-term daily preventative anti-aging care for sensitive skin.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] This invention relates to the field of cosmetic technology, specifically to a mild composition for preventive anti-aging of sensitive skin, its preparation method, and its application. Background Technology

[0002] Skin aging is the most direct external manifestation of bodily aging. Its core mechanisms involve decreased dermal fibroblast activity, reduced synthesis of type I and type III collagen, upregulation of matrix metalloproteinase (MMP) expression leading to extracellular matrix degradation, slowed epidermal renewal rate, and inflammatory aging resulting from the accumulation of chronic low-grade inflammation in tissues. These mechanisms do not operate in isolation but are coupled through a vicious cycle of "external stimulation → barrier damage → activation of inflammatory signals → extracellular matrix degradation → further weakening of the barrier," continuously accelerating the aging process. Therefore, an ideal anti-aging strategy not only needs to promote collagen regeneration but also needs to block the generation of stimuli and inflammatory signals upstream, repair and strengthen the skin's own barrier function, and avoid disrupting the skin's tolerance balance during long-term use.

[0003] Currently, the most widely recognized mainstream anti-aging active ingredients are retinol and high-concentration vitamin C. Retinol, by binding to retinoic acid receptors in the nucleus, regulates cell differentiation, proliferation, and extracellular matrix-related gene expression, strongly promotes collagen synthesis and inhibits MMPs, and is considered the gold standard ingredient for anti-aging. High-concentration vitamin C, as a powerful antioxidant, scavenges reactive oxygen species and participates in processes such as proline hydroxylation in collagen synthesis. However, both types of ingredients have significant skin irritation: retinol can cause skin stinging, burning, erythema, and peeling, which most people with sensitive skin cannot tolerate, and due to its photostability, it can only be used at night and requires strict sun protection; high-concentration vitamin C requires a low pH environment to ensure stability and transdermal activity, and its acidic environment poses a clear irritation to sensitive skin with a fragile barrier. Furthermore, the formula is prone to oxidation and discoloration, affecting user compliance. Therefore, there is a significant conflict between the anti-aging efficacy and gentle safety of current mainstream anti-aging products, failing to meet the needs of people with sensitive skin for long-term safe anti-aging care.

[0004] The proportion of people with sensitive skin continues to rise globally. Epidemiological surveys show that over 50% of women and approximately 40% of men report experiencing skin sensitivity issues. For this group, weakened skin barrier function is itself an early sign of accelerated aging—decreased integrity of the stratum corneum lipid bilayer leads to increased transepidermal water loss (TEWL), making it easier for external irritants and allergens to penetrate, triggering innate immune responses and chronic inflammation. This, in turn, accelerates dermal matrix degradation and cellular aging through inflammatory aging mechanisms. In practical skincare, people with sensitive skin are often advised to adopt a phased approach: "repair the skin barrier first, and then consider anti-aging after the sensitivity subsides." However, this strategy has an inherent flaw: barrier repair often takes months or even longer. During this period, continuous external stimuli and endogenous aging effects do not cease; in fact, the weakened barrier function may accelerate the aging process, systematically delaying the timing of anti-aging intervention.

[0005] To avoid the high irritation of retinol and highly acidic ascorbic acid, several alternative solutions have emerged in existing technologies, targeting sensitive skin or seeking gentle anti-aging. The first type focuses on moisturizing care aimed solely at barrier repair, concentrating on replenishing physiological lipids and moisturizing factors, but lacking active anti-aging activity. The second type uses plant-derived anti-inflammatory and soothing ingredients alone; while temporarily relieving sensitivity symptoms, their anti-inflammatory effects are insufficient and they lack the ability to promote collagen regeneration. The third type uses gentle anti-aging ingredients, represented by peptides, which are well-tolerated but have a single target and lack the synergistic effect of barrier repair and blocking the source of inflammation. The fourth type uses gentle antioxidants such as non-acidic vitamin C derivatives or low-concentration vitamin E; while less irritating, their anti-aging mechanisms are mostly limited to basic free radical scavenging, lacking upstream intervention functions such as activating collagen synthesis signals or repairing DNA damage.

[0006] Furthermore, published patent documents also contain attempts to combine some of the aforementioned components. For example, CN121796303A discloses a composition with Bacillus fermentation products, bakuchiol, edamame seed extract, and cherry blossom extract as active ingredients, claiming multiple effects such as anti-glycation, anti-oxidation, anti-aging, and moisturizing. Although this solution includes the anti-inflammatory effect of bakuchiol, the overall anti-aging logic focuses on anti-glycation and anti-oxidation, lacking active intervention in the repair of the stratum corneum lipid structure, making it difficult to break the vicious cycle of "stimulation invasion → chronic inflammation → barrier weakening" in sensitive skin. Its efficacy verification focuses on collagenase inhibition, moisturizing, and anti-glycation indicators, lacking data support on inflammatory aging and barrier function indicators (TEWL) of sensitive skin. CN121910617A discloses an eye care composition with ectoine and bakuchiol as the core, but its application is strictly limited to the eye area, while the mechanism of aging around the eyes differs from the barrier fragility and chronic inflammatory aging of large areas of sensitive skin on the face. Although this approach integrates the anti-inflammatory and collagen-promoting effects of psoralen and the DNA protection of ectoine, it also lacks the structural reconstruction function of the stratum corneum lipid barrier, resulting in a lack of a stable skin microenvironment as the basis for long-term efficacy in upstream protection and midstream anti-aging.

[0007] In summary, existing technologies reveal that while various gentle ingredient-based solutions have been attempted in the field of anti-aging for sensitive skin, they either limit themselves to barrier repair and lack proactive anti-aging capabilities, or only provide soothing without addressing the root causes of inflammation and aging, or target only a single point of action, making it difficult to construct a synergistic anti-aging system covering multiple functional dimensions with low irritation. While some solutions have achieved preliminary integration in one or two functional dimensions, none have simultaneously covered the three dimensions of preventative blocking of upstream stimuli and DNA damage, inhibition of midstream inflammatory aging signals and activation of collagen regeneration, and structural reconstruction of the downstream stratum corneum barrier. Summary of the Invention

[0008] Developing a composition that integrates upstream preventive protection, midstream inflammation suppression and collagen activation, and downstream barrier structure reconstruction into a synergistic system while ensuring low skin irritation is a pressing technical challenge in this field. This would overcome systemic defects in existing technologies, such as dispersed functional targets, lack of anti-aging closed loop, and time window delays caused by the "repair first, then fight aging" strategy.

[0009] The technical problem this invention aims to solve is: how to provide a composition that combines high gentleness with multi-target synergistic effects, enabling it to simultaneously achieve preventative blocking of upstream aging signals, effective activation of midstream collagen regeneration activity, and structural reconstruction of downstream skin barrier function, thereby providing a preventative anti-aging solution for long-term daily use for people with sensitive skin. Based on this, this invention provides a gentle composition for preventative anti-aging of sensitive skin, its preparation method, and its application.

[0010] This invention systematically integrates ectoine, psoralen liposomes, and ceramide liposomes to construct a triple synergistic functional architecture of "upstream preventive blocking - midstream active anti-aging - downstream barrier structural reconstruction." In this architecture, ectoine is positioned at the upstream of the aging signaling chain—by ​​protecting the activity of heat shock proteins, repairing DNA damage caused by ultraviolet radiation and external environmental stimuli, and inhibiting TRPV1-mediated neurogenic inflammation, it blocks the malignant transformation of external stimuli into inflammatory aging signals from the source. Psoralen acts at the midstream signaling pathway level—as a PPAR-γ agonist, it inhibits NF-κB activation to reduce the release of pro-inflammatory factors such as IL-6 and IL-8, while promoting type I collagen synthesis and inhibiting matrix metalloproteinase activity, thereby achieving active anti-aging effects. Ceramide is positioned at the downstream tissue structure level—directly participating in the structural reconstruction of the intercellular lipid bilayer of the stratum corneum, restoring the integrity of the physical barrier, thereby consolidating and maintaining the anti-aging results achieved by upstream and midstream interventions. These three elements form a complete anti-aging closed loop from three levels: molecular pathways, cellular function, and tissue structure.

[0011] To achieve the simultaneous exertion of the aforementioned three functions, this invention employs a differentiated delivery strategy: psoralen and ceramide are encapsulated in liposomes and introduced into the system, while ectoine exists in free form. Psoralen liposomes penetrate the skin to the deep epidermis and dermis, releasing the drug slowly, effectively avoiding potential irritation caused by excessively high local concentrations of free psoralen, while also prolonging its effective duration of action. Ceramide liposomes, due to their high biocompatibility with stratum corneum lipids, are targeted and delivered to the intercellular lipid region of the stratum corneum, achieving precise in-situ replenishment of barrier lipids. Free ectoine rapidly forms a hydration protective film in the stratum corneum and upper epidermis, providing immediate cellular protection. This layered delivery design enables the three active ingredients to achieve precise spatial positioning and temporal orderly release at different skin layers, enhancing overall efficacy while further ensuring the gentleness of the composition.

[0012] The objective of this invention can be achieved through the following technical solutions: This invention first provides a mild composition for preventive anti-aging of sensitive skin, comprising ectoine, psoralen liposome suspension, and ceramide liposome suspension; wherein the mass ratio of ectoine, psoralen liposome suspension to ceramide liposome suspension is (0.01~4):(0.01~6):(0.01~7). The psoralen liposome suspension contains psoralen liposomes, the psoralen liposomes include a membrane material and psoralen encapsulated in the membrane material, and the mass ratio of solvent to psoralen in the psoralen liposome suspension is (15~20):1. The ceramide liposome suspension contains ceramide liposomes, which include a membrane material and ceramide encapsulated within the membrane material. The mass ratio of solvent to ceramide in the ceramide liposome suspension is (10~20):1.

[0013] In some embodiments of the present invention, preferably, the mass ratio of the ectoine, psoralen liposome suspension to the ceramide liposome suspension is (0.1~2):(0.1~4):(0.1~5).

[0014] In some embodiments of the present invention, more preferably, the mass ratio of the ectoin, psoralen liposome suspension to the ceramide liposome suspension is (0.5~2):(2~4):(3~5).

[0015] Ectoin exists in free form in the compositions of this invention and is not incorporated into the liposome encapsulation system. Ectoin exhibits good water solubility and excellent stability, allowing for effective distribution in the stratum corneum and upper epidermis without the need for a carrier. Furthermore, its molecular chaperone function requires direct interaction with water molecules and proteins in its free molecular form to be effective. Free ectoin can rapidly form a hydration protective film in the superficial layer of the stratum corneum, achieving immediate cellular protection, complementing the release timing of psoralen and ceramides slowly released by liposomes.

[0016] In some embodiments of the present invention, the membrane material of the psoralen liposome includes phospholipids and cholesterol, wherein the phospholipids are selected from at least one of soybean lecithin, hydrogenated lecithin, and phosphatidylcholine, and preferably, the phospholipids are hydrogenated lecithin; The mass ratio of the phospholipids, cholesterol, and psoralen is (3~5):(0.5~1.5):1.

[0017] In some embodiments of the present invention, the psoralen liposome suspension is prepared from phospholipids, cholesterol, psoralen, and water, and the preparation method is as follows: Phospholipids, cholesterol, and psoralen are dissolved in an organic solvent. The organic solvent is removed to form a phospholipid film containing psoralen. Water is added for hydration, and the mixture is homogenized under high pressure to obtain a psoralen liposome suspension. The mass ratio of phospholipids, cholesterol, and psoralen is (3~5):(0.5~1.5):1, and the mass ratio of water to psoralen is (15~20):1.

[0018] In some embodiments of the present invention, the phospholipid is selected from at least one of soybean lecithin, hydrogenated lecithin, and phosphatidylcholine, and preferably, the phospholipid is hydrogenated lecithin.

[0019] In some embodiments of the present invention, when preparing the psoralen liposome suspension, the organic solvent is anhydrous ethanol, the dissolution temperature is 40~50℃, and the anhydrous ethanol is removed by vacuum rotary evaporation; the hydration temperature is 40~50℃, the hydration time is 30~60 minutes; the high-pressure homogenization pressure is 500~1200 bar, and the homogenization cycle is 3~8 times.

[0020] In some embodiments of the present invention, the ceramide liposome suspension is prepared from ceramide, phospholipids, cholesterol, hexyldecyl alcohol, glycerol, and water, and the preparation method is as follows: Phospholipids, cholesterol, ceramides and hexyldecyl alcohol are dissolved in an organic solvent, the organic solvent is removed to form a mixed film containing ceramides, water containing glycerol is added for hydration, and the mixture is homogenized under high pressure to obtain a ceramide liposome suspension. The mass ratio of phospholipids, cholesterol, ceramides and hexyldecyl alcohol is (2~4):(0.5~1.5):(1~2.5):(0.5~1.5). The mass ratio of water containing glycerol to ceramide is (10~20):1, and glycerol accounts for 5%~20% of the total mass of water containing glycerol.

[0021] In some embodiments of the present invention, the ceramide is selected from one or more of ceramide NP, ceramide AP, ceramide NS, and ceramide EOP, and preferably, the ceramide is ceramide NP; The phospholipid is selected from at least one of soybean lecithin, hydrogenated lecithin, and phosphatidylcholine, preferably hydrogenated lecithin.

[0022] In some embodiments of the present invention, when preparing the ceramide liposome suspension, the organic solvent is anhydrous ethanol, the dissolution temperature is 60~70℃, and the anhydrous ethanol is removed by vacuum rotary evaporation; the hydration temperature is 45~55℃, the hydration time is 40~60 minutes; the high-pressure homogenization pressure is 600~1200 bar, and the homogenization cycle is 5~10 times.

[0023] In preparing psoralen liposome suspension and ceramide liposome suspension, this invention can simulate the compositional characteristics of physiological lipids in the stratum corneum by rationally setting the dosage relationship between the liposome membrane material and the core components, which is beneficial to the fusion of liposomes with the skin barrier structure and the targeted release of active ingredients.

[0024] The present invention further provides a method for preparing the mild composition for preventive anti-aging of sensitive skin, comprising the following steps: Preparation of psoralen liposome suspension: Phospholipids, cholesterol, and psoralen are dissolved in an organic solvent. The organic solvent is removed to form a phospholipid film. Water is added for hydration, and the mixture is homogenized under high pressure to obtain a psoralen liposome suspension. Preparation of ceramide liposome suspension: Phospholipids, cholesterol, ceramide, and hexyldecyl alcohol are dissolved in an organic solvent. The organic solvent is removed to form a mixed film. Water containing glycerol is added for hydration, and the mixture is homogenized under high pressure to obtain a ceramide liposome suspension. Ectoin is dissolved in an aqueous phase and mixed with the psoralen liposome suspension and the ceramide liposome suspension to obtain the mild composition.

[0025] This invention provides a more specific method for preparing a psoralen liposome suspension: Hydrogenated lecithin, cholesterol, and psoralen are weighed in a mass ratio of (3-5):(0.5-1.5):1, placed in a container, and an appropriate amount of anhydrous ethanol is added. The mixture is stirred in a water bath at 40-50°C until completely dissolved, yielding a clear organic phase solution. Ethanol is removed by rotary evaporation under vacuum at 40-50°C until a uniform, transparent phospholipid film forms on the container wall. Water preheated to 40-50°C is added to the container for hydration, with a water-to-psoralen mass ratio of (15-20):1. Hydration is performed by rotary hydration under normal pressure for 30-60 minutes, allowing the film to fully swell and detach, yielding a crude liposome suspension. The crude suspension is transferred to a high-pressure homogenizer and homogenized 3-8 times at 500-1200 bar pressure to obtain the psoralen liposome suspension.

[0026] This invention provides a more specific method for preparing a ceramide liposome suspension: Hydrogenated lecithin, cholesterol, ceramide NP, and hexyldecyl alcohol are weighed in a mass ratio of (2-4):(0.5-1.5):(1-2.5):(0.5-1.5), placed in a container, and an appropriate amount of anhydrous ethanol is added. The mixture is stirred in a water bath at 60-70°C until completely dissolved, yielding a clear organic phase solution. The ethanol is removed by rotary evaporation under vacuum at 60-70°C until a uniform and transparent phospholipid-ceramide mixed film forms on the container wall. Glyceryl-containing water preheated to 45-55°C is added to the container for hydration. The mass ratio of glyceryl-containing water to ceramide is (10-20):1, with glycerol accounting for 5%-20% of the total mass of the glyceryl-containing water. Hydration is carried out by rotary hydration under normal pressure for 40-60 minutes, allowing the film to fully swell and detach, yielding a crude ceramide liposome suspension. The obtained crude suspension was transferred to a high-pressure homogenizer and homogenized 5 to 10 times at a pressure of 600 to 1200 bar to obtain the ceramide liposome suspension.

[0027] The present invention further provides the use of the mild composition described herein for preventive anti-aging of sensitive skin in the preparation of cosmetics for preventive anti-aging of sensitive skin.

[0028] The present invention further provides a cosmetic for preventive anti-aging of sensitive skin, comprising a base excipient and an active ingredient, wherein the active ingredient comprises the mild composition for preventive anti-aging of sensitive skin; in the cosmetic for preventive anti-aging of sensitive skin, the mass fraction of ectoine is 0.25-8%, the mass fraction of bakuchiol liposome suspension is 1-12%, and the mass fraction of ceramide liposome suspension is 1.5-14%. Preferably, the mass fraction of ectoine is 0.5-4%, the mass fraction of bakuchiol liposome suspension is 2-6%, and the mass fraction of ceramide liposome suspension is 3-7%.

[0029] The cosmetics mentioned are serums, lotions, face creams, facial mask serums, or ampoules.

[0030] Furthermore, the matrix excipients are selected from one or more of the following: humectants, thickeners, emollients, emulsifiers, skin conditioners, pH adjusters, preservatives, chelating agents, fragrances, and solvents.

[0031] The moisturizer is selected from one or more of the following: glycerin, propylene glycol, butylene glycol, pentanediol, hexanediol, 1,2-pentanediol, 1,3-propanediol, 1,2-hexanediol, panthenol, dipropylene glycol, octyl glycol, octyldodecanol, betaine, sorbitol, xylitol, polyethylene glycol, glyceryl polyether-26, trehalose, mannitol, glyceryl glucoside, and glucose.

[0032] The thickener is selected from one or more of the following: carbomer, xanthan gum, acrylate / C10-30 alkanol acrylate crosspolymer, sodium acrylate / sodium acryloyldimethyl taurate copolymer, ammonium acryloyldimethyl taurate / VP copolymer, hydroxyethyl cellulose, and sodium polyacrylate.

[0033] The emollient is selected from one or more of the following: caprylic / capric triglyceride, isohexadecane, squalane, isostearate isopropyl ester, shea butter, polydimethylsiloxane, cyclopentadimethylsiloxane, vinyldimethylsiloxane, polymethylsilsesquioxane, polydimethylsiloxane alcohol, glyceryl caprylate, isopropyl palmitate, jojoba seed oil, meadowfoam seed oil, camellia seed oil, phytosterols / behenol / octyldecyl lauroyl glutamate.

[0034] The emulsifier is selected from one or more of cetearyl alcohol, glyceryl stearate, glyceryl stearate SE, PEG-100 stearate, stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, cetearyl glucoside, sorbitan oleate, glyceryl stearate, potassium cetyl phosphate, polysorbate-20, lauryl ether-7, and sodium stearoyl glutamate.

[0035] The skin conditioning agent is selected from one or more of sodium hyaluronate, hydrolyzed hyaluronic acid, acetylated sodium hyaluronate, tocopheryl acetate, phytosphingosine, dipotassium glycyrrhizate, allantoin, and bisabolol.

[0036] The pH adjuster is selected from one or more of arginine, triethanolamine, sodium hydroxide, potassium hydroxide, citric acid, and sodium citrate.

[0037] The preservative is selected from one or more of p-hydroxyacetophenone, phenoxyethanol, benzoic acid, potassium sorbate, and sodium benzoate.

[0038] The chelating agent is selected from one or more of disodium EDTA, tetrasodium EDTA, and tetrasodium glutamate diacetate.

[0039] The fragrance is a daily-use fragrance.

[0040] The solvent is deionized water.

[0041] This invention does not simply involve physically mixing ectoine, bakuchiol, and ceramides. Instead, it constructs a triple synergistic functional architecture based on the vicious cycle of sensitive skin—"barrier fragility - inflammation accumulation - accelerated aging"—comprising "upstream preventative blocking - midstream proactive anti-aging - downstream barrier structural reconstruction." To ensure the effective operation of this architecture, bakuchiol and ceramides are encapsulated in liposomes, while ectoine exists in a free form, resulting in differentiated skin layer distribution and release sequence, enabling functional coupling of the three components in both space and time of action.

[0042] Ectoin (tetrahydromethylpyrimidine carboxylic acid) is a cyclic amino acid derivative that, as a compatible solute, can maintain the stability of biological macromolecular structures under extreme conditions such as high temperature, high salt, and strong ultraviolet radiation. In this invention, ectoine plays a core role in upstream preventive protection: at the stratum corneum level, it forms a stable hydration shell with surrounding water molecules through polar groups and binds to the polar heads of intercellular lipids in the stratum corneum, constructing a dense hydration protective film in the superficial layer of the stratum corneum, effectively reducing transepidermal water loss and enhancing the skin's physical resistance to external stimuli; at the cellular protection level, ectoine can act as a molecular chaperone to protect the natural conformation and activity of heat shock proteins, enabling them to continue to perform their repair function on denatured proteins under ultraviolet radiation, heat stress, or oxidative stress conditions, while also activating DNA repair enzymes to repair DNA damage such as ultraviolet-induced cyclobutanepyrimidine dimers, thus implementing preventive blocking at the upstream of the chain of "external stimulation → DNA damage → release of inflammatory factors → accelerated aging"; at the anti-inflammatory level, ectoine can inhibit the expression of ultraviolet-induced capsaicin receptor 1 (TRPV1), reducing the burning sensation and redness associated with neurogenic inflammation. In summary, Ectocin shifts the anti-aging intervention point from the traditional "repair after collagen degradation" to "blocking it at the beginning of stimulation signal generation," making it the first line of defense for preventive anti-aging.

[0043] Psoralen is a phloroglucinol terpene compound extracted from the seeds of the legume Psoralea corylifolia. Due to its anti-aging efficacy comparable to retinol and significantly lower irritation, it plays a core role in the midstream active anti-aging process in this invention. At the anti-inflammatory level, psoralen, as an agonist of peroxisome proliferator-activated receptor γ (PPAR-γ), trans-inhibits the transcriptional activation of nuclear factor κB (NF-κB) at the source of the signaling pathway, significantly reducing the release of pro-inflammatory factors such as interleukin-6 (IL-6) and interleukin-8 (IL-8), thus actively intervening at the gene transcription level, rather than merely passively alleviating existing inflammation. At the anti-aging level, psoralen effectively promotes fibroblast activity, stimulates type I collagen synthesis, and simultaneously inhibits the expression of matrix metalloproteinases to reduce the enzymatic degradation of collagen, synergistically maintaining and repairing dermal structure from two directions: "promoting synthesis and inhibiting degradation." Furthermore, psoralen has a strong free radical scavenging ability, neutralizing reactive oxygen species and activating endogenous antioxidant enzyme systems. Ectoin blocks the conversion of external stimuli into inflammatory signals upstream, while bakuchiol further inhibits the transcription of already initiated inflammatory signals. It also repairs the dermal structure by promoting collagen regeneration and inhibiting matrix degradation. Together, they form a deep synergy of "upstream interception and midstream control" in the anti-inflammatory pathway. Bakuchiol endows the composition with the ability to actively reverse skin aging. Its safety profile is significantly superior to traditional retinol, and it is non-photosensitive, making it suitable for long-term daily use on sensitive skin.

[0044] Ceramides are the main components of intercellular lipids in the stratum corneum, accounting for approximately 40%-50% of the lipid matrix in a healthy stratum corneum. Together with cholesterol and free fatty acids, they assemble into a highly ordered lamellar liquid crystal structure, forming the core framework of the skin's physical permeability barrier. Externally, they prevent the invasion of chemical irritants and pathogenic microorganisms; internally, they prevent excessive water evaporation, maintaining the homeostasis of the epidermal environment. With age and the continuous accumulation of external environmental stress, the ceramide content in the skin significantly decreases, leading to structural defects in the stratum corneum lipid bilayer. This manifests as increased transepidermal water loss, increased sensitivity, and a weakened barrier, further accelerating the inflammatory aging process. Supplementing with ceramides consistent with the physiological lipid composition of the skin can directly participate in the structural reconstruction of the barrier lipid bilayer, filling structural gaps in the lipid matrix and restoring the integrity and order of the stratum corneum.

[0045] In the synergistic system of this invention, ceramides are responsible for building a stable physical barrier in the stratum corneum. After ectoin completes the upstream stimulation blocking and bakuchiol completes the midstream anti-inflammatory and collagen activation, the achieved anti-aging results are consolidated to prevent external stimuli from triggering the inflammatory aging chain again. At the same time, it provides a stable skin environment for the continued performance of the first two effects, realizing the key locking function in the complete closed loop of "prevention-repair-reconstruction".

[0046] Regarding the delivery strategy, this invention employs liposomes to encapsulate bakuchiol and ceramides, while ectoine exists in a free form. The design logic is as follows: after bakuchiol is encapsulated in liposomes, it can slowly penetrate into the deep epidermis and dermis to release the active ingredient, avoiding potential irritation caused by excessively high local concentration peaks in the free state, while prolonging the effective duration of action and protecting its chemical stability; ceramides have a high melting point and are prone to recrystallization in conventional matrices. Encapsulation in liposomes can effectively solve their solubility and formulation stability issues. Liposomes, with their high biocompatibility with stratum corneum lipids, can achieve in-situ precise delivery to barrier targets; ectoine, due to its good water solubility and stability, can be effectively distributed in the stratum corneum and upper epidermis without a carrier, and its molecular chaperone function requires direct interaction with water molecules and proteins in the form of free molecules to be effective. The free state is conducive to its rapid formation of an immediate hydration protective film and cell protection effect. The three elements thus form a temporal complementarity of "rapid and immediate protection in the free state - sustained and long-lasting effect of liposomes", which improves efficacy while further ensuring the mildness of the composition.

[0047] Compared with the prior art, the present invention has the following advantages and beneficial effects: Unlike traditional anti-aging products that are designed for normal skin and are unsuitable for sensitive skin due to their potential irritation, this invention specifically targets sensitive skin as its core user group and aims for preventative anti-aging. The composition is free of known irritating ingredients such as retinol and high-concentration acids. Bakuchiol is non-photosensitive and safe for daytime use. The overall formula is extremely low in irritation, requires no tolerance-building period, and is suitable for long-term daily care for sensitive skin.

[0048] This application utilizes the synergy of ectoine, psoralen liposomes, and ceramide liposomes to form a complete anti-aging closed loop across three levels: molecular pathways, cellular function, and tissue structure. By combining the above-mentioned triple synergistic mechanism with a layered delivery system, this invention shifts the focus of anti-aging intervention from the traditional "passive repair after damage accumulation" to "active prevention before aging signals are triggered," providing a systematic preventive anti-aging technology solution for the sensitive skin field.

[0049] The composition provided by this invention achieves comprehensive anti-aging effects encompassing multiple dimensions, including moisturizing, repairing, anti-inflammatory, anti-wrinkle, and elasticity enhancement, while maintaining low irritation. Unlike the traditional phased care strategy of "repairing the skin barrier first, then combating aging," this invention moves the anti-aging intervention point forward to "blocking the stimulus signal at its inception" through the upstream protective mechanism of ectoine. This forms a closed loop with the midstream anti-aging effects of bakuchiol and the downstream reconstruction effects of ceramides, allowing individuals with sensitive skin to initiate anti-aging care without waiting for complete barrier repair. This avoids the risk of cumulative aging caused by time window delays in phased strategies, achieving a simultaneous intervention mode of "repairing and combating aging simultaneously." Attached Figure Description

[0050] Figure 1 The image shows the reddish tinge on the front of the emulsion used in Example 2.

[0051] Figure 2 Image showing facial redness after 7 days of using the lotion from Example 2.

[0052] Figure 3 Image showing facial redness after 28 days of using the emulsion from Example 2.

[0053] Figure 4 Comparison images of facial redness at different times after using the lotion of Example 2.

[0054] Figure 5 Image of C-Cube crow's feet before using the emulsion in Example 2.

[0055] Figure 6 Image showing crow's feet after 7 days of using the C-Cube emulsion from Example 2.

[0056] Figure 7 Image of crow's feet after 28 days of using the C-Cube emulsion from Example 2.

[0057] Figure 8 Comparison of C-Cube crow's feet wrinkles after using the emulsion of Example 2 for different periods of time. Detailed Implementation

[0058] The present invention will now be described in detail with reference to the accompanying drawings and specific embodiments.

[0059] Unless otherwise specified, the raw materials and testing methods involved in this invention are commonly used in the field.

[0060] Example 1: The application of a mild composition for preventive anti-aging of sensitive skin in the preparation of cosmetics, specifically providing a lotion for preventive anti-aging of sensitive skin, comprising base excipients and active ingredients.

[0061] The composition of the emulsion raw materials provided in Example 1 is shown in Table 1.

[0062] Table 1. Proportion of each component in the emulsion of Example 1 The preparation method of psoralen liposome suspension is as follows: Hydrogenated lecithin, cholesterol, and psoralen are weighed in a mass ratio of 4:1:1 and placed in a round-bottom flask. An appropriate amount of anhydrous ethanol is added, and the mixture is stirred in a 45°C water bath until completely dissolved, yielding a clear organic phase solution. Ethanol is removed by rotary evaporation under vacuum at 45°C until a uniform and transparent phospholipid film forms on the flask wall. Water preheated to 45°C is added to the flask, with a water-to-psoralen mass ratio of 15:1. The mixture is then rotary hydrated under normal pressure for 45 minutes to allow the film to fully swell and detach, yielding a crude liposome suspension. The crude suspension is transferred to a high-pressure homogenizer and homogenized five times at 800 bar to obtain the psoralen liposome suspension.

[0063] The preparation method of ceramide liposome suspension is as follows: Hydrogenated lecithin, cholesterol, ceramide NP, and hexyldecyl alcohol are weighed in a mass ratio of 3:1:1.5:1 and placed in a round-bottom flask. An appropriate amount of anhydrous ethanol is added, and the mixture is stirred in a 65°C water bath until completely dissolved, yielding a clear organic phase solution. Ethanol is removed by rotary evaporation under vacuum at 65°C until a uniform, transparent phospholipid-ceramide mixed film forms on the flask wall. Preheated water containing glycerol (preheated to 50°C) with a glycerol-to-ceramide mass ratio of 12:1 and glycerol accounting for 10% of the total mass of the water containing glycerol, is added to the flask. The mixture is then hydrated by rotary evaporation under normal pressure for 50 minutes to allow the film to fully swell and detach, yielding a crude ceramide liposome suspension. The obtained crude suspension is transferred to a high-pressure homogenizer and homogenized 8 times at 900 bar to obtain the ceramide liposome suspension.

[0064] The preparation method of the lotion for preventive anti-aging of sensitive skin in this embodiment includes the following steps: (1) Add each component of phase A to a water pot, heat to 80°C at a stirring speed of 500 rpm, keep warm and stir for 30 minutes until the acrylic (ester) / C10-30 alkanol acrylate crosspolymer is fully swollen, sodium hyaluronate and xanthan gum are fully hydrated, and sodium acrylate / acryloyl dimethyl taurate copolymer is fully dispersed to form a uniform phase A mixture.

[0065] (2) Add each component of phase B to the oil pot, heat it to 80°C at a stirring speed of 300 rpm, keep it warm and stir for 15 minutes until it is completely melted and mixed evenly to form a uniform phase B mixture.

[0066] (3) At a stirring speed of 300 rpm, phase B is slowly drawn into phase A and mixed evenly. Then, the mixture is homogenized and emulsified at 3000 rpm for 5 minutes to form a uniform emulsion. After homogenization, the mixture is stirred and cooled at a stirring speed of 300 rpm.

[0067] (4) When the temperature drops to 60°C, add the premixed C phase components (arginine, disodium EDTA, fragrance, p-hydroxyacetophenone) at a stirring speed of 300 rpm, and stir for 12 minutes until completely dissolved and mixed evenly.

[0068] (5) Continue stirring at 300 rpm to cool down to 38°C, add each component of phase D (ectoin, psoralen liposome suspension, ceramide liposome suspension), stir for 20 minutes until uniform, and discharge to obtain the emulsion for preventive anti-aging of sensitive skin.

[0069] Examples 2-3, Comparative Examples 1-6, and Blank Example 1 The only difference between Example 2 and Example 1 is the addition of each effective component (i.e., the D phase component in Table 1), and the only difference between Example 3 and Example 1 is the reduction of each effective component.

[0070] The difference between Comparative Examples 1-3 and Example 3 is that only one key composition component (i.e., the D phase component in Table 1) is missing. The difference between Comparative Examples 4-6 and Example 3 is that only two key composition components are missing. The difference between Blank Example 1 and Example 3 is that all key composition components are missing.

[0071] The specific proportions of Examples 2-3, Comparative Examples 1-6 and Blank Example 1 are shown in Table 2-3, and the preparation method is the same as that of Example 1.

[0072] Table 2. Raw material composition ratios for Examples 1-3 Table 3 shows the raw material composition ratios of Comparative Examples 1-6 and Blank Example 1. Human efficacy testing 1. Test Samples and Objects Emulsions were prepared from Examples 1-3, Comparative Examples 1-6, and Blank Example 1, which were prepared according to the raw material composition ratios in Table 2-3.

[0073] Thirty participants aged 30-55 years were recruited. All participants reported a history of skin sensitivity and a positive lactic acid sting test, had no systemic diseases or active facial dermatitis, and signed informed consent forms.

[0074] The subjects were randomly divided into 10 groups of 3 people each, corresponding to 10 test samples from Examples 1-3, Comparative Examples 1-6 and Blank Example 1.

[0075] 2. Usage and Testing Methods After cleansing their face morning and evening, participants applied an appropriate amount of the assigned test sample evenly to their face and neck, gently massaging until absorbed, for 28 consecutive days. During the testing period, participants were prohibited from using other anti-aging or functional cosmetics on the test areas and were advised to avoid prolonged sun exposure.

[0076] Follow-up tests were conducted on the skin redness effect before use (D0), on the 7th day after use (D7), and on the 28th day after use (D28). Before each test, the subjects cleaned their faces with a uniformly provided facial cleanser and sat quietly for 30 minutes in a constant temperature and humidity environment (temperature 20-22℃, relative humidity 40%-60%) before the following indicators were measured.

[0077] (1) Skin stratum corneum moisture content: The Corneometer CM825 skin moisture meter was used to measure the bilateral cheekbone area of ​​the subject. Three measurements were taken on each side and the average value was taken.

[0078] (2) Transepidermal water loss rate (TEWL): The Tewameter TM300 transepidermal water loss meter was used to measure the bilateral zygomatic region of the subjects. Three measurements were taken on each side and the average value was taken.

[0079] (3) Degree of skin redness: Facial photos were taken using the VISIA-CR skin imaging system, and the proportion of facial erythema area was calculated through the red area analysis module.

[0080] (4) Skin elasticity: The R2 value of skin elasticity in the cheekbone area of ​​the subject was measured using a Cutometer MPA580 skin elasticity meter. Three measurements were taken on each side and the average value was taken.

[0081] (5) Skin wrinkle volume: The total wrinkle volume of the crow's feet area and nasolabial fold area on both sides of the subject was analyzed using the EvaFACE three-dimensional facial imaging system, and the crow's feet area image was captured using the C-Cube skin imaging system.

[0082] 3. Test Results 3.1 Skin stratum corneum moisture content Table 4. Change rate (%) of skin stratum corneum moisture content after sample use in each group of subjects. As shown in Table 4, the stratum corneum moisture content of all subjects increased after 28 days of sample use compared to baseline (D0), but the magnitude of the increase varied significantly between groups. The increases in moisture content observed in Examples 1-3 were significantly better than those in the comparative examples and the control group. Example 2 showed the largest increase, reaching 34.52% at D28, followed by Example 1 at 28.61%, and then Example 3 at 21.38%, exhibiting a clear dose-dependent relationship. The increases in moisture content in Comparative Examples 1-3 ranged from 15% to 17%, generally higher than the 10% to 11% increases in Comparative Examples 4-6, while the increase in control example 1 was only 5.33%. These results indicate that the examples maximized the moisturizing effect through the synergistic effect of the upstream hydration protective film formed by ectoine in the stratum corneum, the downstream barrier lipid replenishment by ceramide liposomes, and the anti-inflammatory protection of bakuchiol. In the comparative examples, the increase in moisture content decreased significantly regardless of the absence of any component, verifying the necessity of the synergistic effect of the three components in constructing a stable skin moisturizing system.

[0083] 3.2 Transepidermal water loss rate Table 5. Changes in transepidermal water loss rate (%) after sample use in each group of subjects (compared to D0; negative values ​​indicate decrease / improvement). As shown in Table 5, the TEWL values ​​of all groups showed a decreasing trend during the 28-day usage period. The TEWL reduction of Examples 1-3 was significantly better than that of the comparative examples and the blank example. Example 2 showed the largest TEWL reduction, reaching 24.74% at D28, followed by Example 1 at 20.38%, and Example 3 at 15.47%. The TEWL reduction of Comparative Examples 1-3 ranged from 11% to 13%, Comparative Examples 4-6 ranged from 7% to 9%, while the blank example 1 only showed a reduction of 3.39%. The TEWL reduction effect of the examples was significantly better than that of the comparative examples containing only one or two components, indicating that the synergistic effect of the three components at the upstream protection, midstream anti-inflammatory, and downstream reconstruction levels can jointly maintain the barrier integrity and achieve the maximum reduction of TEWL. The absence of any component weakens the barrier repair effect.

[0084] 3.3 Degree of skin redness Table 6 shows the rate of change in skin redness after each group of subjects used the sample.

[0085] Table 6. Change rate of skin redness after sample use in each group of subjects (%, compared with D0, negative values ​​indicate reduced redness). Depend on Figure 1-4 As shown in Table 6, the redness of the skin in all groups of subjects was reduced to varying degrees after 28 days of use. Examples 1-3 showed the most significant reduction in redness, reaching 11% to 16% at day 28. Comparative examples 1-3 were next, at 8% to 9%, and comparative examples 4-6 were next, at 6% to 7%. The blank example showed the weakest reduction, approximately 3.51%. The data indicate that the redness improvement effect of the examples was significantly better than all comparative examples and the blank example. The three components have a synergistic effect on the anti-inflammatory pathway: psoralen inhibits the release of inflammatory factors at the source through the PPAR-γ / NF-κB pathway; ectoine reduces neurogenic inflammation by inhibiting TRPV1 expression; and the stable barrier repaired by ceramides reduces the entry of external stimuli and lowers the frequency of inflammation triggering at the source. In the comparative examples, the redness improvement effect was significantly reduced regardless of the absence of any component, verifying the irreplaceable role of the three components in anti-inflammatory and redness-reducing effects.

[0086] Figure 1 The image shows the reddish tinge on the front of the emulsion used in Example 2. Figure 2 Images showing facial redness after 7 days of using the lotion from Example 2. Figure 3 Image showing facial redness after 28 days of using the emulsion from Example 2. Figure 4 The images show a comparison of facial redness at different times after using the lotion of Example 2. Taking Example 2, which showed the most significant improvement, as an example, before use (D0), the subject had diffuse patchy erythema on both cheeks and sides of the nose, with indistinct borders, and the erythema area accounted for approximately 15%-20% of the total facial area. Figure 1 After 7 days of continuous use (D7), the area of ​​facial erythema significantly decreased, the color changed from bright red to dark red or light pink, the borders became less blurred, and some areas only had punctate erythema. Figure 2 After 28 days of use (D28), facial erythema had largely subsided, with only a very slight faint redness remaining at the highest point of the cheekbones in a few subjects. Overall skin tone evenness was significantly improved, with no obvious color difference from normal areas. Figure 3 The imaging results were consistent with the trends of the quantitative data in Table 6, directly confirming the rapid and sustained improvement effect of the composition of the present invention on redness in sensitive skin.

[0087] 3.4 Skin elasticity Table 7. Changes in skin elasticity (%, compared to D0) in each group of subjects after sample use. As shown in Table 7, the skin elasticity R2 value improvement of Examples 1-3 was significantly better than that of the comparative examples and the blank example. Example 2 showed the greatest elasticity improvement, reaching 18.43% at D28, followed by Example 1 at 15.47%, and then Example 3 at 12.62%. The elasticity improvement of Comparative Examples 1-3 ranged from 9% to 10%, Comparative Examples 4-6 ranged from 7% to 8%, and the blank example 1 showed only 1.93%. The elasticity improvement effect of the examples was significantly better than that of the comparative examples, indicating that the three components synergistically provide systemic support for dermal matrix health: ectoine maintains fibroblast activity through DNA damage repair and HSP protection, psoralen promotes collagen regeneration and inhibits collagen degradation, and ceramides construct a stable skin internal environment to ensure the continued efficacy of the former two. In the comparative examples, the three components were incomplete, and the elasticity improvement effect was significantly reduced.

[0088] 3.5 Skin wrinkle volume Table 8. Change rate of skin wrinkle volume after sample use in each group of subjects (%, compared with D0, negative values ​​indicate a reduction in wrinkle volume). As shown in Table 8, after 28 days of sample use, the volume of crow's feet and nasolabial folds in all groups decreased compared to D0, but the reduction rate varied significantly between groups. Examples 1-3 showed the most significant wrinkle improvement: Example 2 reduced crow's feet volume by 4.33% and nasolabial fold volume by 5.68%; Example 1 reduced by 3.57% and 4.74%, respectively; and Example 3 reduced by 2.69% and 3.46%, respectively. Comparative Examples 1-3 showed significantly weaker wrinkle improvement than the examples, with crow's feet volume decreasing by approximately 1.8% to 2.0% and nasolabial fold volume decreasing by approximately 2.2% to 2.5%. Comparative Examples 4-6 showed further weakening, with crow's feet volume decreasing by approximately 1.2% and nasolabial fold volume decreasing by approximately 1.8%. Blank Example 1 showed almost no substantial improvement, with crow's feet volume decreasing by only 0.43% and nasolabial fold volume decreasing by only 0.52%. The results showed that the wrinkle improvement effect could only be maximized when the three components were combined completely: ectoine protected fibroblasts from UV and oxidative damage upstream, psoralen promoted collagen regeneration and inhibited collagen degradation midstream, and ceramide built a stable barrier downstream to consolidate the anti-aging results. In the comparative example, the wrinkle improvement effect was significantly reduced regardless of which component was missing, verifying the necessity of the three components synergistically forming a complete anti-aging closed loop of prevention-repair-reconstruction.

[0089] In Example 2, the C-Cube skin imaging system was used to acquire high-resolution three-dimensional images of the crow's feet area of ​​the subject. Figure 5 Image of C-Cube crow's feet before using the emulsion in Example 2. Figure 6 Image showing crow's feet after 7 days using the C-Cube emulsion from Example 2. Figure 7 Image showing crow's feet after 28 days using the C-Cube emulsion from Example 2. Figure 8 Comparison images of C-Cube crow's feet wrinkles at different times after using the lotion in Example 2. Before use (D0), clear radial fine lines were visible on the outer corners of the eyes of the subjects, with significant depth. Multiple lines intertwined to form a network structure, and the skin surface was uneven. Figure 5 After 7 days of continuous use (D7), the depth of wrinkles was significantly reduced, some shallower wrinkles became discontinuous, the original reticular areas showed a tendency to separate, and the smoothness of the skin surface improved. Figure 6 After 28 days of use (D28), fine lines have largely disappeared, leaving only very faint, barely visible lines. The overall skin texture is smooth, and the boundary between the skin and the surrounding normal skin is blurred. Figure 7 The imaging changes were highly consistent with the quantitative data on wrinkle volume, confirming that the composition of the present invention can significantly reduce the volume and depth of fine lines around the eyes in people with sensitive skin within 28 days.

[0090] Based on the analysis results of the above five indicators, Examples 1-3 were significantly superior to the comparative examples and the blank in terms of increasing skin stratum corneum moisture content, reducing transepidermal water loss (TEWL), alleviating redness, improving elasticity, and reducing wrinkles. A clear dose-dependent relationship was observed, i.e., Example 2 was superior to Example 1, and Example 1 was superior to Example 3. A time-dependent relationship was also observed, i.e., the effect on D28 was superior to D7, and D7 was superior to D0. After 28 days of use, the composition of Example 2 of this invention increased skin stratum corneum moisture content by 34.52%, reduced transepidermal water loss (TEWL) by 24.74%, reduced skin redness by 15.74%, increased skin elasticity R2 value by 18.43%, reduced crow's feet volume by 4.33%, and reduced nasolabial fold volume by 5.68%. Comparative Examples 1-3 were generally superior to Comparative Examples 4-6, and Comparative Examples 4-6 were generally superior to Blank Example 1. In all indicators, the effect of Example 3 was superior to that of Comparative Examples 1-3, fully demonstrating that the three-component synergistic system of this invention is not a simple summation of the effects of each component, but rather produces a substantial synergistic effect. From an overall efficacy perspective, the three components each perform their respective functions and work synergistically: ectoine is responsible for upstream preventative blocking, psoralen undertakes midstream active anti-aging, and ceramide completes downstream barrier structural reconstruction—the absence of any one of them disrupts the synergistic closed loop, significantly reducing overall efficacy. The above human clinical data fully validates the technical advantages and indivisibility of this invention's prevention-repair-reconstruction triple synergistic system.

[0091] The above description of the embodiments is provided to enable those skilled in the art to understand and use the invention. It will be apparent to those skilled in the art that various modifications can be made to these embodiments, and the general principles described herein can be applied to other embodiments without inventive effort. Therefore, the present invention is not limited to the above embodiments, and any improvements and modifications made by those skilled in the art based on the disclosure of the present invention without departing from the scope of the invention should be within the protection scope of the present invention.

Claims

1. A mild composition for preventative anti-aging of sensitive skin, characterized in that, The suspension includes ectoine, psoralen liposome suspension, and ceramide liposome suspension; the mass ratio of ectoine, psoralen liposome suspension to ceramide liposome suspension is (0.01~4):(0.01~6):(0.01~7). The psoralen liposome suspension contains psoralen liposomes, the psoralen liposomes include a membrane material and psoralen encapsulated in the membrane material, and the mass ratio of solvent to psoralen in the psoralen liposome suspension is (15~20):

1. The ceramide liposome suspension contains ceramide liposomes, which include a membrane material and ceramide encapsulated within the membrane material. The mass ratio of solvent to ceramide in the ceramide liposome suspension is (10~20):

1.

2. The mild composition for preventative anti-aging of sensitive skin according to claim 1, characterized in that, The mass ratio of the ectoine, psoralen liposome suspension to the ceramide liposome suspension is (0.1~2):(0.1~4):(0.1~5). More preferably, the mass ratio of the ectoine, psoralen liposome suspension to the ceramide liposome suspension is (0.5~2):(2~4):(3~5).

3. A mild composition for preventative anti-aging of sensitive skin according to claim 1, characterized in that, The psoralen liposome suspension is prepared from phospholipids, cholesterol, psoralen, and water, and its preparation method is as follows: Phospholipids, cholesterol, and psoralen are dissolved in an organic solvent. The organic solvent is removed to form a phospholipid film containing psoralen. Water is added for hydration, and the mixture is homogenized under high pressure to obtain a psoralen liposome suspension. The mass ratio of phospholipids, cholesterol, and psoralen is (3~5):(0.5~1.5):1, and the mass ratio of water to psoralen is (15~20):

1.

4. A mild composition for preventative anti-aging of sensitive skin according to claim 3, characterized in that, Choose one or both of the following conditions: (1) The phospholipid is selected from at least one of soybean lecithin, hydrogenated lecithin, and phosphatidylcholine, preferably hydrogenated lecithin; (2) The organic solvent is anhydrous ethanol, the dissolution temperature is 40~50℃, and the anhydrous ethanol is removed by rotary evaporation under reduced pressure; the hydration temperature is 40~50℃, the hydration time is 30~60 minutes; the high pressure homogenization pressure is 500~1200 bar, and the homogenization is repeated 3~8 times.

5. A mild composition for preventative anti-aging of sensitive skin according to claim 1, characterized in that, The ceramide liposome suspension is prepared from ceramide, phospholipids, cholesterol, hexyldecyl alcohol, glycerol, and water, and its preparation method is as follows: Phospholipids, cholesterol, ceramides and hexyldecyl alcohol are dissolved in an organic solvent, the organic solvent is removed to form a mixed film containing ceramides, water containing glycerol is added for hydration, and the mixture is homogenized under high pressure to obtain a ceramide liposome suspension. The mass ratio of phospholipids, cholesterol, ceramides and hexyldecyl alcohol is (2~4):(0.5~1.5):(1~2.5):(0.5~1.5). The mass ratio of water containing glycerol to ceramide is (10~20):1, and glycerol accounts for 5%~20% of the total mass of water containing glycerol.

6. A mild composition for preventative anti-aging of sensitive skin according to claim 5, characterized in that, Choose one or more of the following conditions: (1) The ceramide is selected from one or more of ceramide NP, ceramide AP, ceramide NS, and ceramide EOP, preferably, the ceramide is ceramide NP; (2) The phospholipid is selected from at least one of soybean lecithin, hydrogenated lecithin, and phosphatidylcholine, preferably hydrogenated lecithin; (3) The organic solvent is anhydrous ethanol, the dissolution temperature is 60~70℃, and the anhydrous ethanol is removed by rotary evaporation under reduced pressure; the hydration temperature is 45~55℃, the hydration time is 40~60 minutes; the high pressure homogenization pressure is 600~1200 bar, and the homogenization is repeated 5~10 times.

7. The use of the mild composition for preventive anti-aging of sensitive skin according to any one of claims 1 to 6 in the preparation of cosmetics for preventive anti-aging of sensitive skin.

8. A cosmetic product for preventative anti-aging of sensitive skin, characterized in that, It includes a matrix excipient and an active ingredient, wherein the active ingredient includes any one of the mild compositions for preventive anti-aging of sensitive skin according to claims 1 to 6; In the cosmetic product for preventive anti-aging of sensitive skin, the mass fraction of ectoine is 0.25-8%, the mass fraction of psoralen liposome suspension is 1-12%, and the mass fraction of ceramide liposome suspension is 1.5-14%. Preferably, the mass fraction of ectoine is 0.5-4%, the mass fraction of psoralen liposome suspension is 2-6%, and the mass fraction of ceramide liposome suspension is 3-7%.

9. A cosmetic product for preventative anti-aging of sensitive skin according to claim 8, characterized in that, The cosmetics mentioned are serums, lotions, face creams, facial mask serums, or ampoules.

10. A cosmetic product for preventative anti-aging of sensitive skin according to claim 8, characterized in that, The matrix excipients are selected from one or more of the following: humectants, thickeners, emollients, emulsifiers, skin conditioning agents, pH adjusters, preservatives, chelating agents, fragrances, and solvents. The moisturizer is selected from one or more of the following: glycerin, propylene glycol, butylene glycol, pentanediol, hexanediol, 1,2-pentanediol, 1,3-propanediol, 1,2-hexanediol, panthenol, dipropylene glycol, octyl glycol, octyldodecanol, betaine, sorbitol, xylitol, polyethylene glycol, glyceryl polyether-26, trehalose, mannitol, glyceryl glucoside, and glucose. The thickener is selected from one or more of the following: carbomer, xanthan gum, acrylate / C10-30 alkanol acrylate crosspolymer, sodium acrylate / sodium acryloyldimethyl taurate copolymer, ammonium acryloyldimethyl taurate / VP copolymer, hydroxyethyl cellulose, and sodium polyacrylate. The emollient is selected from one or more of the following: caprylic / capric triglyceride, isohexadecane, squalane, isostearate isopropyl ester, shea butter, dimethicone, cyclopentamethicone, vinyldimethicone, polymethylsilsesquioxane, dimethicone alcohol, glyceryl caprylate, isopropyl palmitate, jojoba seed oil, meadowfoam seed oil, camellia seed oil, phytosterols / behenol / octyldecyl lauroyl glutamate; The emulsifier is selected from one or more of the following: cetearyl alcohol, glyceryl stearate, glyceryl stearate SE, PEG-100 stearate, stearic acid, palmitic acid, stearyl alcohol, cetyl alcohol, behenyl alcohol, cetearyl glucoside, sorbitan oleate, glyceryl stearate, cetyl phosphate potassium, polysorbate-20, lauryl ether-7, and sodium stearoyl glutamate. The skin conditioning agent is selected from one or more of the following: sodium hyaluronate, hydrolyzed hyaluronic acid, acetylated sodium hyaluronate, tocopheryl acetate, phytosphingosine, dipotassium glycyrrhizate, allantoin, and bisabolol. The pH adjuster is selected from one or more of arginine, triethanolamine, sodium hydroxide, potassium hydroxide, citric acid, and sodium citrate; The preservative is selected from one or more of p-hydroxyacetophenone, phenoxyethanol, benzoic acid, potassium sorbate, and sodium benzoate; The chelating agent is selected from one or more of disodium EDTA, tetrasodium EDTA, and tetrasodium glutamate diacetate. The fragrance agent is a daily-use fragrance. The solvent is deionized water.

Citation Information

Patent Citations

  • Anti-saccharification and anti-aging composition suitable for sensitive skin and application of anti-saccharification and anti-aging composition

    CN121796303A

  • Ectoine-containing composition for periocular care and application thereof

    CN121910617A